# OnCo record navigate (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/navigate/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "navigate", "NCT02576431" ;
  schema:name "NAVIGATE"@en ;
  schema:description "The basket trial behind the first tumour-agnostic TRK inhibitor approval: larotrectinib shrank tumours in three of four patients whatever the organ, as long as the cancer carried an NTRK gene fusion."@en ;
  schema:url <https://onco.cc/trials/navigate/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02576431>, <https://doi.org/10.1056/NEJMoa1714448> ;
  onco:status "positive" ;
  onco:phase "2" ;
  schema:startDate "2015-09-30" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/>, <https://onco.cc/cancers/ntrk-fusion-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/ntrk/> ;
  onco:drugs <https://onco.cc/drugs/larotrectinib/> ;
  onco:companies <https://onco.cc/companies/bayer/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-navigate-j-clin-invest-2021/> .